This content was published on September 22, 2022 – 10:56 am
New York, Sept. 22 (EFE) .- Pfizer lab announced Thursday that it has agreed to provide up to six million treatments of its drug Paxlovid, an oral antiviral against covid-19, to the non-governmental organization Global Fund to improve its access is fair in low- and middle-income countries.
Paxlovid, which greatly reduces the chances of hospitalization or death of a person at high risk of developing severe covid, will be available so that some of the 132 countries in that income category can buy it at a price the pharmaceutical company doesn’t make a deal with. profit.
The company expects doses to begin shipping this year, depending on regulatory approval or clearance by local authorities and the country’s demand and allocations determined by the Global Fund.
The Global Fund, which will devote most of its projects to the fight against AIDS, tuberculosis and malaria, will make the drugs available through its covid-19 response mechanism (C19RM), which has enabled those countries to access tests, treatments, protective equipment and other health products.
Pfizer said it is committed to achieving equal access to Paxlovid, for which it is implementing a strategy for which another similar agreement was signed earlier this year, with UNICEF, to provide four million treatments to low- and middle-income countries earlier this year. year.
The company also said it has a voluntary licensing agreement with the Medicines Patent Pool (MPP), an organization that promotes the production of vaccines in low-income countries, to allow for the development and distribution of generic versions of Paxlovid.
Pfizer CEO Albert Bourla said it is important to improve access to oral antivirals as a safe and effective treatment option for high-risk patients around the world, describing the agreement with the Global Fund as a “step forward. key”. – and middle-income countries. EFE
nqs / jgb
� EFE 2022. The redistribution and redistribution of all or part of the contents of the EFE services is expressly prohibited, without the prior and express consent of Agencia EFE SA
–
